News tagged ‘BreastCancer’ clear
- A new iPhone app launched by Apple today will provide physician researchers with instant data from breast cancer survivors with a goal of providing patients improved post-treatment quality of life.
Tags: BreastCancer, Survivorship
- A study by Dana-Farber Cancer Institute scientists indicates that the pool of patients who can benefit from the drug olaparib is potentially much wider — and offers a ready means of identifying them.
Tags: BreastCancer, OvarianCancer
- A new study finds many breast cancer patients don't know the characteristics of their own disease, such as cancer stage and tumor grade.
Tags: BreastCancer, PatientEducation
- Dana-Farber researchers report women with small, HER2-positive breast tumors who received a combination of lower-intensity chemotherapy and a targeted drug following surgery were highly unlikely to have the cancer recur within three years.
Tags: BreastCancer, TargetedTherapy
- In a clinical trial involving women with triple-negative breast cancer, patients who received the drugs carboplatin and/or bevacizumab in combination with standard chemotherapy prior to surgery were more likely to have their tumors disappear entirely from the breast, according to data presented by investigators during the 2014 San Antonio Breast Cancer Symposium.
- Adding a PI3K inhibitor to hormonal therapy for metastatic breast cancer may help overcome resistance to the hormonal therapy and delay disease progression, according to investigators from Dana-Farber Cancer Institute.
- The Centers for Disease Control and Prevention’s (CDC) Division of Cancer Prevention and Control (DCPC) has awarded a $1.75 million 5 year grant to the Program for Young Women with Breast Cancer at Dana-Farber Cancer Institute to increase the awareness of breast cancer among women and enhance the support services for those diagnosed and treated. The Program for Young Women with Breast Cancer at Dana-Farber was one of only seven organizations to be awarded this competitive grant.
Tags: BreastCancer, Grants
- The American Society of Clinical Oncology (ASCO) today issued a new clinical practice guideline on chemotherapy and targeted therapy for women with HER2-negative advanced breast cancer. The guideline provides detailed, evidenced-based information on the efficacy and side effects of various therapies.
- Practice-changing clinical research conducted at the Dana-Farber Cancer Institute Department of Biostatistics and Computational Biology was featured at the 2014 American Society of Clinical Oncology (ASCO) Annual Meeting Plenary Session.
Tags: BreastCancer, ProstateCancer
- Ursula Matulonis, MD, and colleagues report a two-drug combination that disrupts critical signaling circuits in cancer cells has produced an observable benefit in patients with recurrent high-grade serous ovarian cancer (HGSC) or triple-negative breast cancer (TNBC).
Tags: BreastCancer, CervicalCancer